ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839016 (A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the phase III trial (NCT04839016), the outbreak of coronavirus disease 2019 (COVID-19) inevitably caused vunakizumab interruption in patients with psoriasis. This study extracted the data from Huashan Hospital, where almost all patients experienced drug interruption, and aimed to explore the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis and the impact of treatment interruption. A total of 90 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 65) or placebo (n = 25) were enrolled. Patients in the placebo group were switched to vunakizumab treatment at week (W)12. The 75% or more improvement in the Psoriasis Area Severity Index (PASI 75), PASI 90, and PASI 100 response rates at W12 were higher in the vunakizumab group than in the placebo group. This trend was observed at most time points over 52 weeks. Dermatology life quality index (DLQI) score, DLQI 0/1 response rate, and itch numerical rating scale score at W4, W8, and W12 were improved in the vunakizumab group compared to the placebo group. The incidence of adverse events during the induction period was numerically lower in the vunakizumab group than the placebo group. Sixty-four (98.5%) patients in the vunakizumab group experienced drug interruption, with 59 (92.2%) patients due to COVID-19 pandemic. All patients in the placebo group experienced any-cause drug interruption. In the vunakizumab group, elevated frequency of drug interruption was related to reduced PASI 75 and PASI 90 response rates at W52. Despite the high drug interruption rate in Huashan Hospital during COVID-19 pandemic, vunakizumab shows acceptable efficacy and safety for treating patients with moderate-to-severe plaque psoriasis. However, the long-term efficacy of vunakizumab appears attenuated in this single-center cohort compared with the overall phase III trial population.
Indexed as
Identifiers
42557368What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.